Maria Grazia Roncarolo spent some time with the #biomarker newsletter folks last week, detailing her personal journey in discovering her passion for science, and her lifelong mission to cure #autoimmunity. She also speaks on her discovery of #tr1 #tregs and their applications in medicine and the #science of advancing #cell and #gene therapies from bench to clinic. Read more below! Dylan Neel Utsarga (Tito) Adhikary
Biomarker interview with Maria Grazia Roncarolo, Professor at Stanford University School of Medicine and co-founder, President/Head of R&D at Tr1X We discuss Dr. Roncarolo's training as a physician-scientist, and work on gene therapies for primary immunodeficiencies and immune tolerance. She walks us through her team's first isolation of the Tr1 regulatory cell from patients, and subsequent characterization at DNAX in 1997. As someone who has worked in the field for decades, she discusses the traditional barriers to cell therapy (both CAR-T and Tregs): including manufacturing, durability, efficacy and patient access. Lastly she covers the exciting work at Tr1X , and the allogeneic platform they are advancing to treat graft versus host disease, and other autoimmune conditions. Now in the clinic, they are testing the hypothesis that these cells can "reset" the immune system and promote endogenous Treg activation, and functional cures. #biomarker #biotech #immunology Utsarga (Tito) Adhikary David de Vries https://lnkd.in/ehWeBAV5